Any of these mutations would prevent signaling in response to IFN-γ and give an advantage to the tumor cells escaping from T cells, thereby resulting in primary resistance to anti-CTLA-4 therapy, and may also be a reason for the resistance to PD-1/PD-L1 blockade therapy. This evidence concerns the gene PDCD1 and neoplasm.